TrialBMJ open2024

Combination of the chemokine receptor type 2 (CCR2) antagonist DMX-200 and candesartan for COVID-19: a randomised controlled trial.

Daniel Vincent O'Hara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.